Biologic therapy in asthma: Entering the new age of personalized medicine

Journal of Asthma

Volumn 51, Issue 7, 2014, Pages 669-676

  Fajt, Merritt L ^a   Wenzel, Sally E ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Asthma; Biologic therapy; Eosinophils; IL 13; IL 5; Interleukin (IL) 4; T helper (Th) 2 cells

Indexed keywords

BIOLOGICAL PRODUCT; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 13; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN 5;

ASTHMA; BIOLOGICAL THERAPY; DRUG EFFICACY; DRUG TARGETING; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HUMAN; INFLAMMATION; PERSONALIZED MEDICINE; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TH2 CELL;

ASTHMA; BIOLOGIC THERAPY; EOSINOPHILS; IL-13; IL-5; INTERLEUKIN (IL)-4; T HELPER (TH)-2 CELLS;

ADULT; ASTHMA; BIOLOGICAL THERAPY; CHILD; HUMANS; IMMUNOGLOBULIN E; INDIVIDUALIZED MEDICINE; INTERLEUKINS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84906255127     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2014.910221     Document Type: Review

References (48)

1. Wenzel SE, Busse WW. Severe asthma: lessons from the severe asthma research program. J Allergy Clin Immunol 2007;19:14-21. (Pubitemid 46043380)
2. National Heart Lung and Blood Institute (NHLBI). National Asthma Education and Prevention Program. Expert Panel Report 3: guidelines for the diagnosis and management of asthma. Full Report; 2007.
3. Wenzel SE, Fahy J, Irvin C, Peters S, Spector S, Szefler S. (writing committee) Proceedings of the ATS Workshop on Refractory Asthma. Am J Resp Crit Care Med 2000;162:2341-2351.
4. Stedman JK, Branger E. Stedman's medical dictionary for the health professions and nursing. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
5. Milgrom H, Fick Jr RB, Su JQ, Reimann JD, Bush RK, Watrous ML, Metzger WJ. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 1999; 341:1966-1973. (Pubitemid 30010404)
6. Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P. Treatment of childhood asthma with antiimmunoglobulin E antibody (omalizumab). Pediatrics 2001;108: E36.
7. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108: 184-190. (Pubitemid 32735398)
8. Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, Gruchalla RS, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011;364: 1005-1015.
9. Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thirlwell J, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18: 254-261. (Pubitemid 32776398)
10. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, Fox H, Surrey K. Efficacy and tolerability of antiimmunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59:709-717. (Pubitemid 38850345)
11. Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, Rosen KE, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011;154:573-582.
12. Boulet LP, Chapman KR, Côté J, Kalra S, Bhagat R, Swystun VA, Laviolette M, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997;155:1835-1840. (Pubitemid 27256106)
13. Fahy, JV, Fleming HE,Wong HH, Liu JT, Su JQ, Reimann J, Fick Jr RB, Boushey HA. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155: 1828-1834. (Pubitemid 27256105)
14. Fahy JV, Cockcroft DW, Boulet LP, Wong HH, Deschesnes F, Davis EE, Ruppel J, et al. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med 1999;160:1023-1027. (Pubitemid 29442047)
15. van Rensen EL, Evertse CE, van Schadewijk WA, van Wijngaarden S, Ayre G, Mauad T, Hiemstra PS, et al. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy 2009;64:72-80.
16. Corren J, Wood RA, Patel D, Zhu J, Yegin A, Dhillon G, Fish JE. Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge. J Allergy Clin Immunol 2011; 127:398-405.
17. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur AK, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:2144-2148.
18. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003;167:199-204. (Pubitemid 36076080)
19. Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, Robinson D, et al; International Mepolizumab Study Group. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007;176:1062-1071. (Pubitemid 350223751)
20. Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yang YH, Donnelly S, Ellwanger A, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci USA 2007;104: 15858-15863. (Pubitemid 350035389)
21. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Koth LL, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009;180: 388-395.
22. Brown HM. Treatment of chronic asthma with prednisolone; significance of eosinophils in the sputum. Lancet 1958;2: 1245-1247.
23. Grünig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard D, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998;282: 2261-2263. (Pubitemid 29004075)
24. Izuhara K, Arima K, Yasunaga S. IL-4 and IL-13: their pathological roles in allergic diseases and their potential in developing new therapies. Curr Drug Targets Inflamm Allergy 2002;1:263-269.
25. Chatila TA. Interleukin-4 receptor signaling pathways in asthma pathogenesis. Trends Mol Med 2004;10:493-499. (Pubitemid 39303622)
26. Fish SC, Donaldson DD, Goldman SJ, Williams CM, Kasaian MT. IgE generation and mast cell effector function in mice deficient in IL-4 and IL-13. J Immunol 2005;174:7716-7724. (Pubitemid 40806277)
27. Wills-Karp M, Finkelman FD. Untangling the complex web of IL- 4- and IL-13-mediated signaling pathways. Sci Signal 2008;1:pe55.
28. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007;370:1422-1431. (Pubitemid 47576168)
29. Gauvreau GM, Boulet LP, Cockcroft DW, Fitzgerald JM, Carlsten C, Davis BE, Deschesnes F, et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med 2011;183:1007-1014.
30. Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J, Wenzel SE, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010;181:788-796.
31. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:1088-1098.
32. Slager RE, Otulana BA, Hawkins GA, Yen YP, Peters SP, Wenzel SE, Meyers DA, Bleecker ER. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor a antagonist. J Allergy Clin Immunol 2012;130:516-522.
33. Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, She D, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 2013;41:330-338.
34. Chibana K, Trudeau JB, Mustovich AT, Hu H, Zhao J, Balzar S, Chu HW, Wenzel SE. IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells. Clin Exp Allergy 2008;38:936-946. (Pubitemid 351725847)
35. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013;368:2455-2466.
36. Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004;113: 101-108. (Pubitemid 38096168)
37. Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, Wardlaw AJ, Green RH. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008;178:218-224.
38. Amelink M, de Groot JC, de Nijs SB, Lutter R, Zwinderman AH, Sterk PJ, ten Brinke A, Bel EH. Severe adult-onset asthma: A distinct phenotype. J Allergy Clin Immunol 2013;132:336-341.
39. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-984.
40. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651-659.
41. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, Wilkins HJ, et al; Res-5-0010 Study Group. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011;184:1125-1132.
42. Gauvreau GM, Boulet LP, Cockcroft DW, Baatjes A, Cote J, Deschesnes F, Davis B, et al. Antisense therapy against CCR3 and the common b chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med 2008;177:952-958. (Pubitemid 351717588)
43. Gauvreau GM, Pageau R, Séguin R, Carballo D, Gauthier J, D'Anjou H, Campbell H, et al. Dose-response effects of TPI ASM8 in asthmatics after allergen. Allergy 2011;66:1242-1248.
44. Imaoka H, Campbell H, Babirad I, Watson RM, Mistry M, Sehmi R, Gauvreau GM. TPI ASM8 reduces eosinophil progenitors in sputum after allergen challenge. Clin Exp Allergy 2011;41: 1740-1746.
45. Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF, Lal P, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013;187:804-811.
46. Nair P, Gaga M, Zervas E, Alagha K, Hargreave FE, O'Byrne PM, Stryszak P, et al; Study Investigators. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy 2012;42:1097-1103.
47. Busse WW, Holgate S, Kerwin E, Chon Y, Feng J, Lin J, Lin SL. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 2013; 188:1294-1302.
48. Licona-Limón P, Kim LK, Palm NW, Flavell RA. TH2, allergy and group 2 innate lymphoid cells. Nat Immunol 2013;14: 536-542.